• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.

作者信息

Bettinger Dominik, Schultheiss Michael, Knüppel Eva, Thimme Robert, Blum Hubert E, Spangenberg Hans Christian

出版信息

Hepatology. 2012 Aug;56(2):789-90. doi: 10.1002/hep.25637. Epub 2012 Jul 6.

DOI:10.1002/hep.25637
PMID:22307848
Abstract
摘要

相似文献

1
Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.
Hepatology. 2012 Aug;56(2):789-90. doi: 10.1002/hep.25637. Epub 2012 Jul 6.
2
Sorafenib use in hepatocellular carcinoma: more questions than answers.索拉非尼用于肝细胞癌治疗：问题多于答案。
Hepatology. 2014 Jul;60(1):15-8. doi: 10.1002/hep.27044.
3
Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma.药物相关不良事件可能预测索拉非尼治疗肝细胞癌的疗效。
Hepatology. 2012 Aug;56(2):790-1. doi: 10.1002/hep.25639. Epub 2012 Jul 6.
4
Sorafenib in clinical practice: evidence-based use or abuse?
Hepatology. 2012 Apr;55(4):1305; author reply 1305-6. doi: 10.1002/hep.25541.
5
Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.索拉非尼联合经动脉化疗栓塞术后右心房受累的肝细胞癌消退
Clin Gastroenterol Hepatol. 2012 Oct;10(10):e83-4. doi: 10.1016/j.cgh.2012.06.031. Epub 2012 Jul 17.
6
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
Asia Pac J Clin Oncol. 2012 Jun;8(2):111-4. doi: 10.1111/j.1743-7563.2012.01551.x.
7
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.索拉非尼在原位肝移植后复发性肝细胞癌中的应用的安全性和可行性。
Oncology. 2010;79(1-2):62-6. doi: 10.1159/000319548. Epub 2010 Nov 11.
8
Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management.索拉非尼治疗肝细胞癌——关注特殊人群及不良事件管理
Z Gastroenterol. 2012 Sep;50(9):1018-27. doi: 10.1055/s-0032-1312771. Epub 2012 Sep 10.
9
'I am not going to live to regret that, am I?' A pseudo-hepatocellular carcinoma case.
Liver Int. 2011 Oct;31(9):1418. doi: 10.1111/j.1478-3231.2011.02590.x. Epub 2011 Jul 13.
10
Sorafenib-induced hepatic encephalopathy.索拉非尼诱发的肝性脑病。
Ann Pharmacother. 2009 Dec;43(12):2121. doi: 10.1345/aph.1M457. Epub 2009 Oct 27.

引用本文的文献

1
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.阿特珠单抗联合贝伐珠单抗治疗晚期 HCC 患者的不良反应作为活性的潜在预测因素。
Target Oncol. 2024 Jul;19(4):645-659. doi: 10.1007/s11523-024-01061-0. Epub 2024 Apr 30.
2
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.肝细胞癌：分子机制、靶向治疗和生物标志物。
Cancer Metastasis Rev. 2023 Sep;42(3):629-652. doi: 10.1007/s10555-023-10084-4. Epub 2023 Feb 2.
3
Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis.
接受吡咯替尼治疗的HER2阳性转移性乳腺癌患者的真实世界结局及预后因素：一项多中心回顾性分析
Breast Cancer (Dove Med Press). 2022 Dec 21;14:491-504. doi: 10.2147/BCTT.S385341. eCollection 2022.
4
TKIs beyond immunotherapy predict improved survival in advanced HCC.TKI 治疗优于免疫治疗，可改善晚期 HCC 患者的生存。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2559-2574. doi: 10.1007/s00432-022-04115-w. Epub 2022 Jun 30.
5
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma.索拉非尼的持久客观反应及序贯治疗在不可切除肝细胞癌中的作用。
Ther Adv Med Oncol. 2022 May 22;14:17588359221099401. doi: 10.1177/17588359221099401. eCollection 2022.
6
Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC).肝细胞癌（HCC）全身治疗的最新进展
Curr Treat Options Gastroenterol. 2021 Jun;19(2):351-368. doi: 10.1007/s11938-021-00346-x. Epub 2021 Mar 31.
7
Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy.雷莫西尤单抗治疗肝细胞癌（HCC）的临床评估：在治疗中的地位。
Onco Targets Ther. 2021 Dec 29;14:5521-5532. doi: 10.2147/OTT.S268309. eCollection 2021.
8
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.索拉非尼治疗期间早期出现腹泻作为考虑尽早换用二线药物的一个指标。
United European Gastroenterol J. 2021 Jul;9(6):655-661. doi: 10.1002/ueg2.12111. Epub 2021 Jul 6.
9
Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion.IMbrave150研究结果对晚期肝细胞癌不断演变的治疗格局的潜在影响：多学科专家意见
J Hepatocell Carcinoma. 2020 Dec 21;7:423-433. doi: 10.2147/JHC.S274930. eCollection 2020.
10
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.基线特征对接受索拉非尼治疗的肝癌患者总生存的影响：十年经验
Gastrointest Tumors. 2019 Oct;6(3-4):92-107. doi: 10.1159/000502714. Epub 2019 Sep 12.